US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
アメリカ
USOTC
Shin Nippon Biomedical Laboratories Ltd (PK) (SBLOF) 銘柄情報

Shin Nippon Biomedical Laboratories Ltd (PK) (SBLOF)

7.00

0.00

( 0.00% )

更新日時： 23:11:23

Shin Nippon Biomedical Laboratories Ltd (PK) (SBLOF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

7.00

( - )

買値

6.95

売値

7.93

出来高

-

0.00 日の範囲 0.00

7.00 52 週間の範囲 12.5728

時価総額

前日終値

7.00

始値

-

時刻

最終取引時間

-

財務取引量

-

VWAP

-

平均取引量 (3 か月)

US$ 257,164

発行済株式数

41,631,814

配当利回り

50 (4.34%)

PER

10.5

1 株当たり利益 (EPS)

109.69

歳入

32.52B

純利益

4.57B

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmace... Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally. It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies. The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels. In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan. 詳細を表示

セクター

Healthcare

業界

Medical Diagnostics & Screening

ウェブサイト

www.snbl.co.jp

本社

Kagoshima, Japan

設立

2026

Shin Nippon Biomedical Laboratories Ltd (PK) is listed in the Healthcare sector of the その他OTC with ticker SBLOF. The last closing price for Shin Nippon Biomedical L... (PK) was US$7. Over the last year, Shin Nippon Biomedical L... (PK) shares have traded in a share price range of US$ 7.00 to US$ 12.5728.

Shin Nippon Biomedical L... (PK) currently has 41,631,814 shares in issue. The market capitalisation of Shin Nippon Biomedical L... (PK) is US$291.42 million. Shin Nippon Biomedical L... (PK) has a price to earnings ratio (PE ratio) of 10.50.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	7	7	7	4000	7	CS
12	-2.1608	-23.5874596105	9.1608	9.1608	7	1000	7	CS
26	-3.03	-30.2093718843	10.03	10.03	7	525	7.10289524	CS
52	-2.36	-25.2136752137	9.36	12.5728	7	210	7.2955572	CS
156	-9.97	-58.750736594	16.97	16.97	7	152	7.4402473	CS
260	-9.97	-58.750736594	16.97	16.97	7	150	7.63870112	CS

SBLOF - Frequently Asked Questions (FAQ)

What is the current Shin Nippon Biomedical Laboratories Ltd (PK) share price?

The current share price of Shin Nippon Biomedical Laboratories Ltd (PK) is US$ 7.00

How many Shin Nippon Biomedical Laboratories Ltd (PK) shares are in issue?

Shin Nippon Biomedical Laboratories Ltd (PK) has 41,631,814 shares in issue

What is the market cap of Shin Nippon Biomedical Laboratories Ltd (PK)?

The market capitalisation of Shin Nippon Biomedical Laboratories Ltd (PK) is USD 291.42M

What is the 1 year trading range for Shin Nippon Biomedical Laboratories Ltd (PK) share price?

Shin Nippon Biomedical Laboratories Ltd (PK) has traded in the range of US$ 7.00 to US$ 12.5728 during the past year

What is the PE ratio of Shin Nippon Biomedical Laboratories Ltd (PK)?

The price to earnings ratio of Shin Nippon Biomedical Laboratories Ltd (PK) is 10.5

What is the cash to sales ratio of Shin Nippon Biomedical Laboratories Ltd (PK)?

The cash to sales ratio of Shin Nippon Biomedical Laboratories Ltd (PK) is 1.47

What is the registered address of Shin Nippon Biomedical Laboratories Ltd (PK)?

The registered address for Shin Nippon Biomedical Laboratories Ltd (PK) is 2438 Miyanoura-cho, Kagoshima, Kagoshima, 891-1394

What is the Shin Nippon Biomedical Laboratories Ltd (PK) website address?

The website address for Shin Nippon Biomedical Laboratories Ltd (PK) is www.snbl.co.jp

Which industry sector does Shin Nippon Biomedical Laboratories Ltd (PK) operate in?

Shin Nippon Biomedical Laboratories Ltd (PK) operates in the Medical Diagnostics & Screening sector

MsnPatriotTrader

MsnPatriotTrader 4分前

I think it was a little over 500 million when it ran, if its the ticker I'm thinking of...went back down to the trips from dilution, co-founder died along with a fire to one of their facilities, and delayed commercialization. So $VMST should be in very good shape long-term, imo.

From

niczar

It’s a sham.

BS Company under the guise of something just legitimate enough to keep the eyes off them.

Probably ran out of Gio ‘s basement .

tedpeele

tedpeele 5分前

Data entry? not sure what you are talking about there and as for the other nonsense -- all I can say is the truth:

This was always and still is an interesting investment story - nothing more, nothing less.

I call it as I see it, and the results speak for themselves.

ace65

Looking thin.....

Teddytropics

Teddytropics 6分前

It's ok to make a mistake..

You were signed in as Mr79 when you thought you were as Hi_Lo..

Mistakes happen us all..

Like getting in a few years early on this and having big old Jason Black bags..

Cann Do American to da MoOoOoOoOoOon!

Karma84

Karma84 6分前

Who can confirm that they actually made 10x on this stock??? Bueller???

https://x.com/coomikeywags/status/2074203410740744313?s=46&t=GJF4mYq9oxQgaoD9fp1cvw

WhatMoney?

WhatMoney? 6分前

Another pointless update. Literally no change other than bloomberg tv being back live instead of a white screen

Large Green

Large Green 7分前

Split T, look at the following Paladin Acq Inc, and you will find the names of Charles Smith, Mathew Boutte, and Peter Frielinger.

https://www.sec.gov/Archives/edgar/data/1876566/0001876566-23-000001-index.htm

...

chuck1418

chuck1418 7分前

let’s go. 7s are thin.

delerious1

delerious1 7分前

This is not FDA Approval but " U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™ • "

Kjv

We need a slapperc

quigley24

quigley24 8分前

5286919 now had 5200000 this morning....Schwab would not let me buy....so they put in 300 thou at 89......been kinda funny it picks up a few then jumps to 95 or so..........all day about 86000 or so....hang in folks

WhatMoney?

WhatMoney? 8分前

In other news, android currently has an update

mm41

1. TPA ex-PSP is the real engagement signal. Headline Transactions per Active Account (TPA) fell 1% to 58.7 — the number the financial press leads with. Strip out low-margin, unbranded PSP processing, and TPA ex-PSP rose 6%. This means the highest-margin cohort — the users who actually tap the brand

PhantomEnchanter891

PhantomEnchanter891 8分前

GB article move the market. You cannot be serious.

mm41

1. TPA ex-PSP is the real engagement signal. Headline Transactions per Active Account (TPA) fell 1% to 58.7 — the number the financial press leads with. Strip out low-margin, unbranded PSP processing, and TPA ex-PSP rose 6%. This means the highest-margin cohort — the users who actually tap the brand

Trooperstocks

Trooperstocks 8分前

$TDTH "Our commitment to Trident has always been measured by the long-term value we believe we can create, not by short-term decisions," said Soon Huat Lim, Founder, Chairman and Chief Executive Officer of Trident. "By converting approximately US$8 million of founder indebtedness into restricted Cla

Trooperstocks

Trooperstocks 8分前

$TDTH "Our commitment to Trident has always been measured by the long-term value we believe we can create, not by short-term decisions," said Soon Huat Lim, Founder, Chairman and Chief Executive Officer of Trident. "By converting approximately US$8 million of founder indebtedness into restricted Cla

chemist72

chemist72 8分前

Ten most common cancers globally: The most common cancers globally are breast, lung, colorectal, prostate, stomach, liver, cervical, thyroid, esophageal, and bladder cancers.

Global Overview
In 2022, excluding non-melanoma skin cancer, there were approximately 18.7 million new

newflow

newflow 9分前

EXO... the minimum should be $30 B + as cautioned by Mr. Folse.JMO.

IPSO_FACTO

IPSO_FACTO 10分前

LOL, the ring leader of the College of Haters is back spouting his nonsense! The same routine lacking in substance! The FDA gave approval nod based on convincing data that will only strengthen in tge coming months and beyond.

Keep throwing punches in tte wind SC8; your bitterness i

nowwhat2

nowwhat2 10分前

https://www.youtube.com/shorts/nv18Yt-VbOc

https://www.youtube.com/shorts/LLY8WP3KV94

DrHigh

DrHigh 10分前

its MM and hedge funds fault. they snuck into NWBO HQ and removed the Enter button from all keyboards. They cannot send any communication. and Amazon has closed down all retail stores around them and they do not know how to order any update computer equipment so they are still using technology from

getReady

getReady 10分前

Yes ,those are the numbers and growing but it does matter who bought them.

Genz2

I’m surprised that Wave doesn’t talk to Google about licensing the Embassy Trust Suite for Google Chromebooks and the management of SEDs and Wave Endpoint Monitor as well!!! And if Google had Wave’s other products, I bet that would bring in a lot of sales for Google!!!! Wave Virtual Smart Card cou

Shin Nippon Biomedical L... (PK)

Silence Therapeutics

Atia Vision Share Class ...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。